Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
1 study found for:    19384299 [PUBMED-IDS]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Unknown † Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia
Conditions: Acute Myelogenous Leukemia;   Myeloid Leukemia in Remission;   Effects of Immunotherapy
Intervention: Biological: Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)
To Top

† Indicates status has not been verified in more than two years